Merck's Phase 3 trial of Keytruda plus chemo met progression-free survival and overall survival goals in platinum-resistant ovarian cancer, including patients with PD-L1–positive tumors.
JPMorgan analysts said President Trump’s "most favored nation" drug pricing order is unlikely to move forward without Congressional support and will likely face legal and industry resistance, limiting its near-term impact on pharma stocks.
Pharma ETFs closely watched as Trump's drug policies stir market volatility. Funds offer sector exposure but differ in risk levels and growth potential.
Tempus AI is gaining traction and on track for profits this year; high short interest and rising institutional activity point to significant upside potential.
The biggest strategic highlight for Tempus AI Inc. (NASDAQ: TEM) during the first quarter was a multi-million dollar deal to build "the world's largest foundation model for oncology."
The approval is based on positive results from a phase 3 trial, which demonstrated that Calquence plus bendamustine and rituximab reduced the risk of disease progression or death by 27% compared to standard-of-care chemoimmunotherapy.
AstraZeneca said on Friday that the full results from the two trials will be shared with regulatory authorities and presented at an upcoming medical meeting.
AstraZeneca posts Q1 revenue of $13.59 billion and a strong EPADS beat; oncology leads growth as China's tax probe and halts the Truqap trial in prostate cancer.
U.S. stock futures are trading flat on Tuesday early-morning, keeping with the broad index averages on Monday, as markets await clarity and more earnings reports to come in over the course of this week.
Biopharma stocks rally along with many of our SMID cap trades. The market situation with pharmaceuticals is even more complicated because we started off with legislation (the IRA) trying to curb rising drug and healthcare costs.
Tempus AI Inc (NASDAQ:TEM) shares are surging Wednesday after the company announced a multi-year collaboration with AstraZeneca PLC (NASDAQ:AZN) and Pathos AI.
Cellectis, backed by AstraZeneca funding and a multi-year cash runway, is advancing its prioritized allogeneic CAR-T pipeline toward pivotal 2025 milestones.
